Article
Biochemistry & Molecular Biology
Qing Ye, Joseph Putila, Rebecca Raese, Chunlin Dong, Yong Qian, Afshin Dowlati, Nancy Lan Guo
Summary: A novel methodology was developed to correlate miRNA expression profiles with tumor progression and chemosensitivity in lung cancer. Hsa-miR-142-3p was identified as a miRNA associated with good prognosis and chemosensitivity in lung cancer patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Qing Ye, Salvi Singh, Peter R. Qian, Nancy Lan Guo
Summary: There are currently no effective biomarkers to select chemotherapy, immunotherapy, and radiotherapy for treating lung cancer patients. This study identified genetic networks containing major immune-checkpoint inhibitors CD27, PD1, and PDL1, and their associated prognostic genes and proliferation genes in lung cancer tumors. A 5-gene prognostic model was developed and validated in extensive cohorts to select patients at a high risk for developing metastasis.
Article
Genetics & Heredity
Xinyi Ma, Chengtao Lou, Junjie Pan, Chengwei Zhou, Xiaodong Zhao, Nan Li, Haihua Tian, Xiaodan Meng
Summary: Increasing studies show the importance of circRNA-related ceRNA regulatory networks in tumorigenesis and cancer progression. In this study, a specific circRNA-miRNA network was constructed for non-small cell lung cancer (NSCLC), and its diagnostic potential was evaluated. Dysregulated serum miRNAs and circRNAs were identified in NSCLC, and combinations of circRNAs and miRNAs showed higher diagnostic value. Higher levels of circ_0008167 were associated with more aggressive NSCLC. This research provides a new strategy for ceRNA-related tumor marker development in other cancers.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2023)
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Qing Ye, Brianne Falatovich, Salvi Singh, Alexey V. Ivanov, Timothy D. Eubank, Nancy Lan Guo
Summary: This study developed a qRT-PCR-based seven-gene microfluidic assay to predict the recurrence risk and therapeutic response in patients with early-stage NSCLC. The transcriptional regulatory network related to the seven-gene signature was identified, and multi-omics network genes were found to be associated with immune infiltration and drug response in NSCLC. The study also identified potential repositioning drugs for NSCLC treatment based on the gene expression of the multi-omics network.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Ya-Sian Chang, Siang-Jyun Tu, Ju-Chen Yen, Ya-Ting Lee, Hsin-Yuan Fang, Jan-Gowth Chang
Summary: The clinical use of RNA-Seq for detecting driver fusion genes may play an important role in the treatment of lung cancer.
Article
Oncology
Giuseppe Giaccone, Yongfeng He
Summary: Lung cancer is the leading cause of cancer related death, with two major histological subtypes, NSCLC and SCLC. Transformation from NSCLC to SCLC can cause treatment resistance, potentially due to therapy-induced changes or clonal selection. This article discusses the potential mechanisms, cell of origin, and genomic alterations in both de novo and transformed SCLC, as well as treatment options including chemotherapy, radiotherapy, TKIs, immunotherapy, and antiangiogenic agents.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Cell Biology
Changhui Li, Jiaqi Zhang, Xiaohua Yang, Cheng Hu, Tianqing Chu, Runbo Zhong, Yinchen Shen, Fang Hu, Feng Pan, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Hai Zhang, Wei Nie, Baohui Han, Xueyan Zhang
Summary: The study has demonstrated the significant role of hsa_circ_0003222 in NSCLC progression and resistance, with its high expression associated with disease stage, metastasis, and patient survival rate. Silencing hsa_circ_0003222 led to reduced stemness-like properties and chemoresistance in tumor cells.
CELL DEATH & DISEASE
(2021)
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
Summary: EGFR-mutated lung adenocarcinoma patients can transform into SCLC after receiving TKI therapy. This study evaluated 9 patients who underwent such transformation and found that they had unique clinical, molecular, and histological characteristics at different time points. The findings are important for understanding the molecular heterogeneity and clinical outcomes of this EGFR TKI resistance subtype.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medical Laboratory Technology
Ziyi Peng, Qiuzhi Hu, Shuai Fang, Xun Zhang, Xin Hong, Lili Tao, Jinchang Pan, Meina Jiang, Huihui Bai, Yinuo Wu, Xiaodong Zhao, Chengwei Zhou, Jun Chen, Ying Han, Zhaohui Gong
Summary: The study identified circTOLLIP as a potential non-invasive biomarker for liquid biopsy in NSCLC, showing significantly down-regulated expression in tumor tissues, blood, and cell lines. Circulating circTOLLIP demonstrated better diagnostic values and stability compared to traditional tumor markers.
CLINICA CHIMICA ACTA
(2021)
Article
Genetics & Heredity
Qingqing Li, Rui Wang, Zhenlin Yang, Wen Li, Jingwei Yang, Zhijie Wang, Hua Bai, Yueli Cui, Yanhua Tian, Zixin Wu, Yuqing Guo, Jiachen Xu, Lu Wen, Jie He, Fuchou Tang, Jie Wang
Summary: This study analyzed the transcriptomic heterogeneity of non-small cell lung cancer (NSCLC) using single-cell RNA sequencing. The results revealed the existence of mixed-lineage tumor cells in some patients, which expressed different types of NSCLC marker genes simultaneously. These mixed-lineage tumor cells showed high plasticity and were associated with poorer prognosis. Additionally, gene signatures specific to mixed-lineage tumor cells were identified. These findings contribute to a better understanding of NSCLC tumor heterogeneity and provide potential treatment strategies.
Review
Medicine, General & Internal
Yimin Wang, Chuling Li, Zimu Wang, Zhaofeng Wang, Ranpu Wu, Ying Wu, Yong Song, Hongbing Liu
Summary: This systematic review evaluated the efficacy and safety of immunotherapy in early and late lung cancer, finding that immunotherapy has better efficacy in early lung cancer compared to advanced lung cancer, especially when combined with chemotherapy. In terms of safety, immunotherapy, either alone or in combination with other therapies, was found to be safer in early lung cancer than in advanced lung cancer.
Article
Multidisciplinary Sciences
Nathan Farrokhian, Jeff Maltas, Mina Dinh, Arda Durmaz, Patrick Ellsworth, Masahiro Hitomi, Erin McClure, Andriy Marusyk, Artem Kaznatcheev, Jacob G. Scott
Summary: In this study, the frequency-dependent interactions between a gefitinib-resistant non-small cell lung cancer population and its sensitive ancestor were measured experimentally. The cost of resistance was found to be insufficient in predicting competitive exclusion, and frequency-dependent growth rate measurements were necessary. Simulations showed that ecological growth effects can influence the predicted extinction time.
Article
Pharmacology & Pharmacy
Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N. Lara, Hong -Wu Chen, Huichang Bi, Ai -Ming Yu
Summary: The research found that miR-22-3p, miR-9-5p, and miR-218-5p are antiproliferative miRNAs targeting non-small cell lung cancer (NSCLC) cells, and they inhibit folate metabolism and alter amino acid metabolism in NSCLC cells. In addition, the inhibition of glucose uptake by miR-22-3p and the reduction of serine biosynthesis from glucose by miR-9-5p and -218-5p were also confirmed. Recombinant miR-22-3p was more effective than miR-9-5p and -218-5p in inhibiting NSCLC cell respiration, glycolysis, and colony formation, without causing any toxicity.
ACTA PHARMACEUTICA SINICA B
(2023)
